RMAM
VRTX icon

Raab & Moskowitz Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$760K Hold
1,701
– – 0.17% 105
2025
Q4 		$771K Hold
1,701
– – 0.17% 107
2025
Q3 		$666K Hold
1,701
– – 0.15% 113
2025
Q2 		$757K Hold
1,701
– – 0.18% 102
2025
Q1 		$825K Hold
1,701
– – 0.21% 94
2024
Q4 		$685K Sell
1,701
-48
-3% -$22.3K 0.17% 103
2024
Q3 		$813K Sell
1,749
-37
-2% -$17.8K 0.21% 93
2024
Q2 		$837K Buy
1,786
+48
+3% +$20.8K 0.23% 87
2024
Q1 		$727K Hold
1,738
– – 0.2% 95
2023
Q4 		$707K Sell
1,738
-27
-2% -$9.97K 0.22% 93
2023
Q3 		$614K Hold
1,765
– – 0.22% 95
2023
Q2 		$621K Hold
1,765
– – 0.21% 94
2023
Q1 		$556K Sell
1,765
-58
-3% -$17.4K 0.2% 98
2022
Q4 		$526K Buy
1,823
+125
+7% +$38.1K 0.2% 101
2022
Q3 		$491K Sell
1,698
-5
-0.3% -$1.44K 0.21% 101
2022
Q2 		$479K Hold
1,703
– – 0.19% 111
2022
Q1 		$444K Buy
1,703
+50
+3% +$11.9K 0.15% 118
2021
Q4 		$363K Hold
1,653
– – 0.12% 129
2021
Q3 		$300K Hold
1,653
– – 0.11% 137
2021
Q2 		$333K Hold
1,653
– – 0.12% 130
2021
Q1 		$355K Buy
1,653
+15
+0.9% +$3.29K 0.14% 115
2020
Q4 		$387K Sell
1,638
-6
-0.4% -$1.38K 0.16% 111
2020
Q3 		$447K Buy
1,644
+4
+0.2% +$1.1K 0.21% 99
2020
Q2 		$476K Sell
1,640
-28
-2% -$7.59K 0.23% 95
2020
Q1 		$396K Hold
1,668
– – 0.22% 98
2019
Q4 		$365K Hold
1,668
– – 0.14% 122
2019
Q3 		$282K Hold
1,668
– – 0.12% 135
2019
Q2 		$305K Hold
1,668
– – 0.14% 132
2019
Q1 		$306K Hold
1,668
– – 0.14% 130
2018
Q4 		$276K Hold
1,668
– – 0.14% 130
2018
Q3 		$321K Hold
1,668
– – 0.13% 129
2018
Q2 		$283K Hold
1,668
– – 0.14% 129
2018
Q1 		$271K Buy
+1,668
New +$272K 0.13% 130

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Raab & Moskowitz Asset Management's VRTX Position: Q1 2026 in Review

Raab & Moskowitz Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 1,701 shares worth $760K. The position accounts for 0.17% of the portfolio, ranked #105.

Raab & Moskowitz Asset Management first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $837K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Raab & Moskowitz Asset Management held 1,701 shares of Vertex Pharmaceuticals worth $760K as of Q1 2026.
  • Raab & Moskowitz Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.17% of Raab & Moskowitz Asset Management's portfolio in Q1 2026, its #105 holding.
  • Raab & Moskowitz Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
  • Raab & Moskowitz Asset Management's Vertex Pharmaceuticals position peaked at $837K in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2026, filed 21 May 2026.